AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases Please visit their website for more information.
*Proprietary Buy Sell Volume Indicator
Our proprietary analysis employs a weighted average approach integrating both functional and technical parameters, tailored to the sector, industry, and microeconomic factors. This methodology assigns dynamic weights to the parameters, with a focus on recent trends, ensuring a nuanced evaluation for informed investment decisions.
| Revenue: $13.56B |
| Revenue Growth (YOY): 18.04% |
| Profit (% of Rev): 81.85% |
| Income (% of Rev): 10.53% |
| Income Growth (YOY): 4.00% |
| Operating Income: $3.31B |
| Operating Cash Flow: $3.38B |
| Annual Dividend Yield: 0.65% |
| Total Assets: $104.92B |
| Total Liabilities: $64.12B |
| Cash & Equivalent: $4.80B |
| Total Debt: $31.56B |
| Debt/Equity: 0.74 |
| Quick Ratio: 0.71 |
| Current Ratio: 0.93 |
| Price/Book: 5.91 |
| Price/Earnings: 42.13 |
| EBITDA: $4.63B |
| EPS: 0.92 |
| : |
Considering all the above parameters, in addition to some of the derived parameters of the stock in conjunction with its sector and macroeconomic conditions, our proprietary Weighted Average AI model gives a rank of Buy.
TheoryofStocks is not registered as an investment advisor with any regulatory authority. The information provided on this Website is for educational purposes only and should not be construed as financial or investment advice. By continuing to use this site, you are agreeing to the Terms of Use and Privacy Policy. Please read our Disclaimer.
Contact @ support@theoryofstocks.com
© 2024 Stock Articles. All rights reserved.